NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for AKEEGA-a dual-action tablet combining niraparib and abiraterone acetate-administered with prednisone. This new treatment is indicated for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).
BRCA mutations are associated with more aggressive forms of prostate cancer and poorer outcomes. The approval of AKEEGA addresses a critical unmet need, offering a new therapeutic option for patients who previously had limited treatment alternatives.
In April 2016, Janssen Biotech Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline in 2019) for exclusive rights to niraparib in prostate cancer.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
